RuiXin Medical Secures Nearly RMB 100 Million in Series D Funding to Advance AI-Powered Vascular Interventional Robotics

Article Source:MedRobot

Reprinting Requirements: Direct reprinting is permitted; please indicate the source at the beginning of the article.

May 27, 2026,Shenzhen Raysightmed Co., Ltd. completed a Series D financing round of nearly RMB 100 million,This round of financing, jointly backed by two-tier local state-owned capital investment platforms in Guangzhou, will support the company in advancing the R&D and commercialization of its intelligent cardiovascular diagnostic and therapeutic pipeline.

# Company Introduction

• Headquarters: Shenzhen, Guangdong

• Corporate Positioning: A medical technology company focused on the cardiovascular precision diagnosis and treatment sector

• Main Business Areas:Integrating artificial intelligence, hemodynamic simulation, and surgical robotic technology to build an integrated intelligent diagnosis and treatment platform for cardiovascular and cerebrovascular diseases, encompassing preoperative diagnosis, intraoperative diagnosis and treatment, and postoperative health management, while establishing a product pipeline for cardiovascular medical devices.

# Product and Technology Introduction

• Core Product Types:AngioQFA Coronary Functional Assessment Product, Raysight Score (CT-FFR) Non-invasive Coronary Functional Assessment Product, Intracardiac Echocardiography (ICE), AI Vascular Interventional Surgical Robot

• Applicable Department or Surgical Setting:Applicable to the cardiovascular department, covering clinical scenarios such as coronary intervention procedures, electrophysiology procedures, and structural heart disease procedures.

• Technical Direction or Problem to be Addressed:Leveraging artificial intelligence and hemodynamic simulation technologies for the assessment of coronary perfusion function and microcirculatory resistance indices, thereby optimizing clinical decision-making for interventional procedures; utilizing AI technology to enhance intracardiac echocardiography imaging quality, completing the full-cycle diagnosis and treatment workflow for cardiovascular diseases, while simultaneously advancing research and development in vascular interventional surgical robotics.

# Product Registration Certificate Status

According toMedRobotAccording to the National Medical Products Administration (NMPA) website, the company's approved medical device registration certificates are listed in the table below:

# Funding History

According toMedRobotAccording to the Qichacha website, the company's financing history is detailed in the table below:

# Patent Status

According toMedRobotAccording to a search on the Qichacha website, the company's patents are listed in the following table: